Exploratory/Proof of Principle Microbiota Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68504
- Midwest Children's Health Research Institue
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Singleton, 1-7 days of age at registration or randomization
- Term infant with appropriate birth weight for gestational age
- Either solely formula fed or exclusively receiving mother's own breast milk
- Signed Informed Consent and Protected Health Information
Exclusion Criteria:
- Caesarean delivery
- Infant was born from a mother with Type 1 diabetes
- History of underlying metabolic or chronic disease or immunocompromised
- Feeding difficulties or history of formula or human milk intolerance
- Signs of acute infection of current use of antibiotics
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Amino acid based infant formula
|
|
|
Experimental: Extensively hydrolyzed casein infant formula
|
|
|
Other: Mother's own breast milk
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fecal microbiota measured at each visit
Time Frame: 8 weeks
|
Sequencing and composition of samples
|
8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body weight measured at each visit
Time Frame: 8 weeks
|
Measurement collected with a calibrated infant scale
|
8 weeks
|
|
Body length measured at each visit
Time Frame: 8 weeks
|
Measurement collected with a standardized length board
|
8 weeks
|
|
Head circumference measured at each visit
Time Frame: 8 weeks
|
Measurement collected with a standardized measuring tape
|
8 weeks
|
|
Parental recall of formula intake at each visit
Time Frame: 8 weeks
|
8 weeks
|
|
|
Stool collection at each visit
Time Frame: 8 weeks
|
Composite measure of pH and short chain fatty acids
|
8 weeks
|
|
Serious adverse events collected throughout the study period
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Jon Vanderhoof, M.D., Mead Johnson and Company
Publications and helpful links
General Publications
- Amari S, Shahrook S, Namba F, Ota E, Mori R. Branched-chain amino acid supplementation for improving growth and development in term and preterm neonates. Cochrane Database Syst Rev. 2020 Oct 2;10(10):CD012273. doi: 10.1002/14651858.CD012273.pub2.
- Kok CR, Brabec B, Chichlowski M, Harris CL, Moore N, Wampler JL, Vanderhoof J, Rose D, Hutkins R. Stool microbiome, pH and short/branched chain fatty acids in infants receiving extensively hydrolyzed formula, amino acid formula, or human milk through two months of age. BMC Microbiol. 2020 Nov 9;20(1):337. doi: 10.1186/s12866-020-01991-5.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 6032 (CTEP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fecal Microbiota
-
NCT06262451Enrolling by invitationFecal Microbiota Transplant
-
NCT04078581WithdrawnFecal Microbiota Transplantation
-
NCT02677649CompletedFecal Microbiota
-
NCT04900051RecruitingFecal Microbiota Transplantation
-
NCT05121285CompletedFecal Microbiota Transplantation
-
NCT07486492Not yet recruitingColorectal Cancer Metastatic | Fecal Microbiota Transplantation
-
NCT03350178TerminatedIntensive Care Units | Fecal Microbiota Transplantation
-
NCT07386795Not yet recruitingChronic Constipation | Constipation - Functional | Fecal Microbiota Transplantation
-
NCT07387952RecruitingChronic Constipation | Constipation - Functional | Fecal Microbiota Transplantation (FMT)
-
NCT06423508RecruitingGut Microbiome | Fecal Microbiota | Variability | Methodology Study | Buffer
Clinical Trials on Amino acid based infant formula
-
NCT04519827Completed
-
NCT02953223CompletedShort Bowel Syndrome | Cow's Milk Protein Allergy | Eosinophilic Gastrointestinal Disorders | Malabsorption/Maldigestion | Multiple Food Allergies
-
NCT07342972Not yet recruitingInfections | Quality of Life | Gastrointestinal Tolerance | Gastrointestinal Symptoms | Anthropometrics
-
NCT06108401Not yet recruitingGastrointestinal Diseases | Infant Nutrition Disorders
-
NCT06395571CompletedGastrointestinal Diseases | Infant Nutrition Disorders
-
NCT02948114Terminated
-
NCT01137877TerminatedHealthy Term Infants
-
NCT05757323Completed